%PDF-1.4
%
40 0 obj
<>
endobj
36 0 obj
<>
endobj
98 0 obj
<>stream
Acrobat Distiller 5.0 for Macintosh
2003-01-07T18:57:29Z
2024-03-29T06:55:37-07:00
2024-03-29T06:55:37-07:00
QuarkXPress. 4.11: AdobePS 8.6 (219)
application/pdf
Heather
2001-1009.feb
uuid:2cf73d84-1dd2-11b2-0a00-cc08278d5b00
uuid:2cf73d86-1dd2-11b2-0a00-1e0000000000
endstream
endobj
25 0 obj
<>
endobj
26 0 obj
<>
endobj
41 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
13 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
16 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
118 0 obj
[121 0 R]
endobj
119 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/T1_0 1 Tf
-0.00011 Tc 0.1689 Tw 9.7 0 0 10 54 713.1616 Tm
[(Evaluation of the measur)36.8 (ement pr)36.8 (operties of the translated)]TJ
0.0479 Tw 0 -1.2 TD
(version \(version 3\):)Tj
/T1_1 1 Tf
8.2787 0 Td
(assessment of reproducibility and validi-)Tj
0.02499 Tw -8.2787 -1.2 Td
[(ty)64.8 (, and responsiveness if applicable.)]TJ
0.0768 Tw 1.2371 -1.2 Td
(The simplified methodology proposed in this study needs)Tj
0.02499 Tw -1.2371 -1.2 Td
(to be evaluated in prospective studies.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 631.1616 Tm
[(1.)-875.1 (Buchbinder R, Bombardier C, )36.8 (Y)99.8 (eung M, )17.7 (T)35 (ugwell P)110.7 (.)-0.1 ( )17.7 (Which outcome)]TJ
1.675 -1.25 Td
(measures should be used in rheumatoid arthritis clinical trials?)Tj
0 -1.25 TD
(Arthritis Rheum 1995;38:1568-80.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Pincus )17.7 (T)74 (, Brooks RH, Callahan LF)79.7 (. Prediction of long-term)]TJ
1.675 -1.25 Td
(mortality in patients with rheumatoid arthritis according to simple)Tj
T*
[(questionnaire and joint count measures. )54.8 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
(1994;120:26-34.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Pincus )17.7 (T)74 (, Callahan LF)79.7 (, Brooks RH. Self-reported questionnaire)]TJ
1.675 -1.25 Td
(scores in rheumatoid arthritis compared with traditional physical,)Tj
T*
[(radiographic and laboratory measures. )54.8 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
[(1987;1)36.9 (10:259-66.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Boers M, )17.7 (T)35 (ugwell P)110.7 (.)-0.1 ( )17.7 (The validity of pooled outcome measures)]TJ
1.675 -1.25 Td
(\(indices\) in rheumatoid arthritis clinical trials. J Rheumatol)Tj
0 Tc 0 Tw T*
(1993;20:568-74.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Guillemin F)79.7 (, Bombardier C, Beaton D. Cross-cultural adaptation of)]TJ
1.675 -1.25 Td
(health-related quality of life measures: literature review and)Tj
T*
(proposed guidelines. J Clin Epidemiol 1993;46:1417-32.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Guillemin F)79.7 (, Bombardier C, Beaton D. Cross-cultural adaptation of)]TJ
1.675 -1.25 Td
(health status measures. Scand J Rheumatol 1995;24:61-3.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.675 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Fries JF)79.7 (, Spitz PW)91.7 (, Kraines RG, Holman HR. Measurement of)]TJ
1.675 -1.25 Td
[(patient outcome in arthritis. )54.8 (Arthritis Rheum 1980;23:137-45.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Meenan RF)79.7 (, Gertman PM, Mason JH. )17.7 (The )54.8 (Arthritis Impact)]TJ
1.675 -1.25 Td
[(Measurement Scales. )54.8 (Arthritis Rheum 1980;23:146-52.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (W)79.9 (are JE, Sherbourne CD. )17.7 (The MOS 36-Item Short-Form Health)]TJ
2.175 -1.25 Td
(Survey \(SF-36\): I: Conceptual framework and item selection. Med)Tj
T*
(Care 1992;30:473-83.)Tj
-0.0369 Tc 0 Tw -2.1381 -1.25 Td
[(11)-36.9 (.)]TJ
-0.00011 Tc 0.02499 Tw 2.0881 0 Td
[(Ferraz MB, Oliveira LM, )54.8 (Araujo PMP)110.7 (, )54.8 (Atra E, )17.7 (T)35 (ugwell P)110.7 (. Cross-)]TJ
0.05 -1.25 Td
(cultural reliability of the physical ability dimension of the Health)Tj
T*
(Assessment Questionnaire. J Rheumatol 1990;17:813-7.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Brand\213o L. Qualidade de vida em artrite reumat\227ide: valida\215\213\
o de)]TJ
2.175 -1.25 Td
[(uma vers\213o do )54.8 (Arthritis Impact Measurement Scales II para a)]TJ
T*
[(l\222ngua portuguesa \(Brasil - )54.8 (AIMS-II\) [thesis]. S\213o Paulo: Escola)]TJ
T*
(Paulista de Medicina-UNIFESP; 1995.)Tj
30.825 54.171 Td
[(13.)-875.1 (Ciconelli RM. )17.7 (T)35 (radu\215\213o para o portugu\220s e valida\215\213o do)]TJ
2.175 -1.25 Td
(question\207rio gen\216rico de avalia\215\213o de qualidade de vida Medi\
cal)Tj
T*
(Outcomes 36-Item Short-form Health Survey \(SF-36\) \(Brasil-)Tj
T*
(SF36\). Rev Bras Reumatologia 1999;39:143-50.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Hochber)17.7 (g MC, Chang R)54.8 (W)91.8 (, Dwosh I, Lindsen S, Pincus )17.7 (T)74 (,)-0.1 ( )17.7 (W)79.9 (olfe F)79.7 (.)]TJ
2.175 -1.25 Td
[(The )54.8 (American College of Rheumatology 1991 revised criteria for)]TJ
T*
(the classification of global functional status in rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1992;35:498-502.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Bombardier C, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
(College of Rheumatology preliminary core set of disease activity)Tj
T*
[(measures for rheumatoid arthritis clinical trials. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1993;36:729-40.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(16.)-875.1 (Fried BJ, Boers M, Baker PRA, for the OMERACT)-257.3 (Committee. )54.8 (A)]TJ
2.175 -1.25 Td
[(method for achieving consensus on RA)-220.2 (outcome measures: the)]TJ
T*
[(OMERACT)-257.3 (conference process. J Rheumatol 1993;20:548-51.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Secherest L, Bay )17.7 (TL, Zaidi SMH. Problems of translation in cross-)]TJ
2.175 -1.25 Td
(cultural research. J Cross-cultural Psychol 1972;3:41-56.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Ferraz MB. Cross-cultural adaptation of questionnaires: what is it)]TJ
2.175 -1.25 Td
(and when should it be performed? J Rheumatol 1997;24:2066-8.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Gonz\207lez )17.7 (VM, Stewart )54.8 (A, Ritter PL, Lorig K. )17.7 (T)35 (ranslation and)]TJ
2.175 -1.25 Td
[(validation of arthritis outcomes into Spanish. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1995;38:1429-46.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Abello-Banfi M, Cardiel MH, Ruiz-Mercado R, )54.8 (Alarc\227n-Segovia)]TJ
2.175 -1.25 Td
(D. Quality of life in rheumatoid arthritis: validation of a Spanish)Tj
T*
[(version of the )54.8 (Arthritis Impact Measurement Scales \(Spanish-)]TJ
T*
(AIMS\). J Rheumatol 1994;21:1250-5.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Perneger )17.7 (TV)128.8 (, Lepl\217ge )54.8 (A, Etter JF)79.7 (, Rougemont )54.8 (A. )17.7 (V)110.8 (alidation of a)]TJ
2.175 -1.25 Td
(French-language version of the MOS 36-Item Short Form Health)Tj
T*
(Survey in young healthy adults. J Clin Epidemiol 1995;48:1051-60.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (W)79.9 (are JE, Gandek B, and the IQOLA)-220.2 (Project Group. )17.7 (The SF-36)]TJ
2.175 -1.25 Td
(Health Survey: development and use in mental health research and)Tj
T*
[(the IQOLA)-220.2 (project. Int J Mental Health 1994;23:49-73.)]TJ
-2.175 -1.25 Td
[(23.)-875.1 (Sullivan M, Karlsson J, )17.7 (W)79.9 (are J. )17.7 (The Swedish SF-36 Health survey)64.8 (.)]TJ
2.175 -1.25 Td
[(I. Evaluation of data quality)64.8 (, scaling assumptions, reliability and)]TJ
T*
(construct validity across general populations in Sweden. Soc Sci)Tj
0 Tc T*
(Med 1995;41:1349-58.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875.1 (Goycochea-Robles MV)128.8 (, Gardu\226o-Espinosa J, )17.7 (V)59.8 (ilchis-Guizar E,)]TJ
2.175 -1.25 Td
[(Ortiz-Alv\207rez O, Bur)17.7 (gos-V)110.8 (ar)17.7 (gas R. )17.7 (V)110.8 (alidation of a Spanish version)]TJ
T*
[(of the Childhood Health )54.8 (Assessment Questionnaire. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1997;24:2242-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875.1 (Ar)17.7 (guedas O, )54.8 (Andersson Gare BA, Fasth )54.8 (A, Porras O. Development)]TJ
2.175 -1.25 Td
[(of a Costa Rican version of the Childhood Health )54.8 (Assessment)]TJ
T*
(Questionnaire. J Rheumatol 1997;24:2233-41.)Tj
ET
1 g
438 770 120 -25 re
f
BT
0 g
/T1_3 1 Tf
0 Tc 0 Tw 20.37 0 0 21 439 753.6089 Tm
(2001-1009-7)Tj
ET
54 54 m
558 54 l
S
BT
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Falc\213o, et al: )17.7 (Adaptation of questionnair)36.8 (es)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(385)Tj
ET
1 g
109.47 58.84 395.98 -10.34 re
f
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS1 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS1 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS1 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS1 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
48 0 obj
<>
endobj
46 0 obj
<>
endobj
58 0 obj
<>
endobj
45 0 obj
<>
endobj
83 0 obj
<>
endobj
102 0 obj
<>
endobj
50 0 obj
<>
endobj
52 0 obj
<>
endobj
43 0 obj
<>stream
HTMo0
;G U%ĥݤ=ML4B~6fvyc6vn=w- ϝ ioۛ )%nu~8ҷ0vcE7'Ƞia^MrڟwbKh.YgrjDBNtϚJb]HWSqLU.Ik5ڊޒf"Ҵ$yV6TJC(#ƆF)%Ҝ"`COyoH=[yai~ k7
endstream
endobj
51 0 obj
<>stream
HU{PSw<u
{[D
U*y,oY J^@H@C@ "e# (U-ζ]Cw3Ιo̜|s7P"B۷pJN 3)kd<}!m0 0!ʥ}e݀ja[kA(.CCA0
^A6Q_ن "H"$u%S(EŇL+Nw0%,l'snW\_{s?vg-F9ε584݅epY90m4%&;?35